Patents by Inventor Katja Zimmermann

Katja Zimmermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
    Patent number: 10179123
    Abstract: The present invention relates to 2-Aryl- and 2-Arylalkyl-benzimidazoles of general formula (I): in which A, R1, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: January 15, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf Panknin, Katja Zimmermann, Roland Neuhaus
  • 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
    Patent number: 10137110
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: November 27, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut Rehwinkel, Sonja Anlauf, Duy Nguyen, Olaf Panknin, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney, Gianna Toschi
  • Benzimidazol-2-amines as MIDH1 inhibitors
    Patent number: 10138226
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: November 27, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut Rehwinkel, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuß, Roland Neuhaus
  • BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF
    Publication number: 20180256576
    Abstract: The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.
    Type: Application
    Filed: March 5, 2018
    Publication date: September 13, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Chantal FÜRSTNER, Jens ACKERSTAFF, Alexander STRAUB, Heinrich MEIER, Hanna TINEL, Katja ZIMMERMANN, Adrian TERSTEEGEN, Dmitry ZUBOV, Raimund KAST, Jens SCHAMBERGER, Martina SCHÄFER, Kirsten BÖRNGEN
  • FUSED IMIDAZOLES AS MIDH1 INHIBITORS
    Publication number: 20180215717
    Abstract: The present invention relates to compounds of general formula (I): in which R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 14, 2016
    Publication date: August 2, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf PANKNIN, Ingo HARTUNG, Hartmut REHWINKEL, Duy NGUYEN, Ludwig ZORN, Petra HELFRICH, Katja ZIMMERMANN, Roland NEUHAUS
  • 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS
    Publication number: 20180207137
    Abstract: The present invention relates to 2-Aryl- and 2-Arylalkyl-benzimidazoles of general formula (I): in which A, R1, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 4, 2016
    Publication date: July 26, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf PANKNIN, Katja ZIMMERMANN, Roland NEUHAUS
  • 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS
    Publication number: 20180201585
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6 and R7 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 12, 2016
    Publication date: July 19, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf PANKNIN, Sven RING, Katja ZIMMERMANN, Roland NEUHAUS
  • N-METHYLBENZIMIDAZOLES AS MIDH1 INHIBITORS
    Publication number: 20180170882
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 21, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Sven RING, Olaf PANKNIN, Katja ZIMMERMANN, Judith GÜNTHER, Lars BÄRFACKER
  • Benzimidazol-2-amines as mIDH1 inhibitors
    Patent number: 9957235
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: May 1, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Rehwinkel, Olaf Panknin, Sven Ring, Sonja Anlauf, Holger Siebeneicher, Duy Nguyen, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus, Paul Matthew Blaney
  • Bicyclically substituted uracils and the use thereof
    Patent number: 9949977
    Abstract: The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: April 24, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Chantal Fürstner, Jens Ackerstaff, Alexander Straub, Heinrich Meier, Hanna Tinel, Katja Zimmermann, Adrian Tersteegen, Dmitry Zubov, Raimund Kast, Jens Schamberger, Martina Schäfer, Kirsten Börngen
  • Bicyclically substituted uracils and the use thereof
    Patent number: 9949978
    Abstract: The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: April 24, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Chantal Fürstner, Jens Ackerstaff, Alexander Straub, Heinrich Meier, Hanna Tinel, Katja Zimmermann, Adrian Tersteegen, Dmitry Zubov, Raimund Kast, Jens Schamberger, Martina Schäfer, Kirsten Börngen
  • Benzimidazol-2-amines as MIDH1 inhibitors
    Patent number: 9951027
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: April 24, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Rehwinkel, Holger Siebeneicher, Sonja Anlauf, Duy Nguyen, Olaf Panknin, Sven Ring, Wolfgang Schwede, Marcus Bauser, Katja Zimmermann, Stefan Kaulfuss, Roland Neuhaus
  • BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS
    Publication number: 20170320861
    Abstract: The present invention relates to benzim-idazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 20, 2015
    Publication date: November 9, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut REHWINKEL, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUß, Roland NEUHAUS
  • 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS
    Publication number: 20170319549
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 21, 2015
    Publication date: November 9, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut REHWINKEL, Sonja ANLAUF, Duy NGUYEN, Olaf PANKNIN, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUSS, Roland NEUHAUS, Paul Matthew BLANEY, Gianna TOSCHI
  • SUBSTITUTED URACILS AS CHYMASE INHIBITORS
    Publication number: 20170267648
    Abstract: The present application relates to novel substituted uracil derivatives, to a method for the production thereof, to the use thereof either alone or in combination for treating and/or preventing diseases, and to the use thereof for producing pharmaceuticals for the treatment and/or prevention of diseases.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 21, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Chantal FÜRSTNER, Jens ACKERSTAFF, Alexander STRAUB, Heinrich MEIER, Hanna TINEL, Katja ZIMMERMANN, Dmitry ZUBOV, Jens SCHAMBERGER
  • Substituted uracils and use thereof
    Patent number: 9751843
    Abstract: Substituted uracil derivatives of the compound of Formula (I), processes for their preparation, their use alone or in combinations for treatment and/or prophylaxis of diseases, and their use for preparing medicaments for treatment and/or prophylaxis of diseases.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: September 5, 2017
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Chantal Fürstner, Jens Ackerstaff, Alexander Straub, Heinrich Meier, Hanna Tinel, Katja Zimmermann, Adrian Tersteegen, Dmitry Zubov, Raimund Kast, Jens Schamberger, Martina Schäfer
  • BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS
    Publication number: 20170197921
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: February 10, 2015
    Publication date: July 13, 2017
    Inventors: Hartmut REHWINKEL, Olaf PANKNIN, Sven RING, Sonja ANLAUF, Holger SIEBENEICHER, Duy NGUYEN, Wolfgang SCHWEDE, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUSS, Roland NEUHAUS, Paul Matthew BLANEY
  • BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS
    Publication number: 20170197922
    Abstract: The present invention relates to benzimidazol-2-amines of general formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: February 10, 2015
    Publication date: July 13, 2017
    Inventors: Hartmut REHWINKEL, Holger SIEBENEICHER, Sonja ANLAUF, Duy NGUYEN, Olaf PANKNIN, Sven RING, Wolfgang SCHWEDE, Marcus BAUSER, Katja ZIMMERMANN, Stefan KAULFUSS, Roland NEUHAUS
  • Substituted uracils as chymase inhibitors
    Patent number: 9695131
    Abstract: Substituted uracil derivatives of formula (I), processes for their preparation, their use alone or in combinations for the treatment and/or prophylaxis of diseases, and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: July 4, 2017
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Chantal Fürstner, Jens Ackerstaff, Alexander Straub, Heinrich Meier, Hanna Tinel, Katja Zimmermann, Dmitry Zubov, Jens Schamberger
  • BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF
    Publication number: 20170020875
    Abstract: The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Chantal FÜRSTNER, Jens ACKERSTAFF, Alexander STRAUB, Heinrich MEIER, Hanna TINEL, Katja ZIMMERMANN, Adrian TERSTEEGEN, Dmitry ZUBOV, Raimund KAST, Jens SCHAMBERGER, Martina SCHÄFER, Kirsten BÖRNGEN